We have described above the seminal function of the CCL5/CCR5 axis on tumor progression in preclinical studies, which can be attenuated by knocking down CCL5, using antibody neutralization, and CCR5 antagonists to block ligand–receptor binding, setting the stage for drugs targeting the CCL5/CCR5 axis to enter clinical trials. This evidence concerns the gene CCR5 and neoplasm.